New uses for brentuximab vedotin and novel antibody drug conjugates in lymphoma

Expert Rev Hematol. 2016 Aug;9(8):767-80. doi: 10.1080/17474086.2016.1205949. Epub 2016 Jul 14.


Introduction: Brentuximab vedotin (BV) is a potent anti-CD30 antibody drug conjugate (ADC) that has been approved in relapsed or refractory Hodgkin lymphoma (HL) after autologous stem cell transplantation (ASCT) and anaplastic large-cell lymphoma (ALCL). Beyond these consolidated indications, BV has been tested in a number of different settings with promising results, leading for example to the recent approval as a consolidation after ASCT in high-risk HL patients.

Areas covered: Main emerging areas of clinical investigation of BV include the use as a single-agent or in combination with bendamustine in first-salvage therapy of HL (bridge to ASCT), in the frontline setting in combination with AVD chemotherapy in HL and with CHP in ALCL, in relapsed or refractory cutaneous T-cell lymphomas and finally in diffuse large B-cell lymphomas (DLBCL) expressing CD30. Moreover, many new ADCs are currently under clinical evaluation, as for example the anti-CD79A polatuzumab vedotin in DLBCL. Expert commentary: In few years BV changed the therapeutic scenario of relapsed or refractory HL and ALCL and is rapidly moving toward first-line approval in combination with standard chemotherapy if ongoing randomized trials will demonstrate improved results. Combination strategies with bendamustine in first-salvage HL and with R-CHP in first-line DLBCL appear very promising.

Keywords: Antibody-drug conjugates; CD30; Hodgkin lymphoma; brentuximab vedotin; cutaneous T-cell lymphoma; diffuse large B-cell lymphoma; non-peripheral T-cell lymphoma; polatuzumab vedotin.

Publication types

  • Review

MeSH terms

  • Antigens, Neoplasm
  • Antineoplastic Agents / pharmacology
  • Antineoplastic Agents / therapeutic use*
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use
  • Brentuximab Vedotin
  • Clinical Trials as Topic
  • Consolidation Chemotherapy
  • Drug Resistance, Neoplasm
  • Hematopoietic Stem Cell Transplantation
  • Hodgkin Disease / drug therapy
  • Humans
  • Immunoconjugates / pharmacology
  • Immunoconjugates / therapeutic use*
  • Ki-1 Antigen / antagonists & inhibitors
  • Lymphoma / diagnosis
  • Lymphoma / drug therapy*
  • Lymphoma / metabolism
  • Lymphoma, Non-Hodgkin / drug therapy
  • Recurrence
  • Salvage Therapy
  • Tetraspanins / antagonists & inhibitors
  • Transplantation, Autologous


  • Antigens, Neoplasm
  • Antineoplastic Agents
  • CD37 protein, human
  • Immunoconjugates
  • Ki-1 Antigen
  • Tetraspanins
  • Brentuximab Vedotin